Member Info for potnak

The timing of the RNS will depend on the content. If bad new, I may come late tomorrow to protect the sp with a long weekend. If positive, it will come first thing or at 11am. We could get one today but I do think they waiting for RF to offload as many as they can, in fact, Id go as far as saying the board might have asked them to. Hit the bottom and bounce back. Strap in!

Are you giving me financial advice, Bull? You don't want to do that, you could lose your fancy paid member badge.

The answer is pretty simple, Bull. The financing might not be an immediate problem if the target is to get to the 1a data readout. I think it's obvious that some negotiations are going on. That's why we have complete radio silence. I have been buying in small chunks since last Aug. I bought yesterday and will buy another 2 or 3 tranches this week. This way, if the SP does keep falling, then, I keep averaging down. If I could predict the bottom, I would buy then but as it stands, any piece of good news will see the SP rise and it might 2 or 3 bag in an instant.

Thanks, HBD, That's how I understood it but wasn't sure so didn't comment. So if double-blinded then Tim and John won't know until the data is available?

Cheers SOG but what happens in p1b that blind?

I don't know enough about the P1 Study to comment but, I'm not sure Tim can say anything other than topline results. Chances are they won't know how the trial is going\gone until the data is released. for a P1 tox study, no news is good news. For the dosing study, the devil will be in the detail and no one will see that until it's ready to be published. But the fact that the SAD\MAD dosing is continuing should give us hope that P1a is good, how good, who knows?

Topline results just mean results reported factually. It doesn't necessarily mean they are good. It's just Tim using the correct terminology.

What are topline results in clinical studies?

Top-Line Data means, with respect to a clinical study, a summary of patient demographic data, data for the primary endpoint, and safety data derived from the unblinded, locked clinical trial database.

Yes, the only price that is important is your buy and sell price. It might be difficult to get past the loss of big paper profits but it is a lesson learned for most here. I can rationalise the low and falling SP, as you say, it allows us to increase our holdings for very little outlay. What I can't rationalise is the potential dilution that may be needed. If a reason to sack Parker was needed, this is it. I'm hoping that some immediate non-dilutive funding can be found to steady the ship as it were before looking for proper funding for 1b. They could do this with loans linked to options and warrants, maybe from the board or HNWI or Parker. Or, Owens could earn their keep by tapping up their contacts in the industry. We'd still need funding for 1b but if 1a is good, that we shouldn't have a problem.

I bought more yesterday and have some funds to buy more this week but maybe we shouldn't help the MM's\RF out? If the MM's can't fill the orders, the liquidity dries up and the only way to bring it back is to drive the SP up. It feels ridiculous even writing this but a 30p SP would see some here doubling their money.

I agree with your sentiments, Trader Matt. A profit is a profit but if the science is good, then anything less than £10 and the shareholders have been robbed and it's another nail in the coffin for AIM.

Also, the blue SP? Whats all that about. has news leaked of an 11 am RNS? or just MM's raising to entice some sells because they have another RF order to fill?

I think it's pretty obvious that some sort of negotiation is going on. When they published the interim results RNS last week, they said WC 25th March. I don't think they have done that before, it's usually a date with as BA states, with a presentation notification. I was and I think we all were under the impression that we had enough cash to see us to the end of 1a so the wording of the RNS last week was worrying as it implied we didn't even have enough cash to get to the end of 1a. If so, where has that cash gone? The complete radio silence says to me that we will get an answer to the immediate questions this week and that for me is getting to the 1a data readout. If good then we'll get funding, if not good then, well I don't know but I think this is a squeeky bum time that no one here would've predicted 2 years ago.

Warthog. The all-time high here is a 300 bagger from today's price. It's the AIM dream and, and considering we are much further down the road, it is worth a punt. Is it risky, of course, it is but no riskier than other AIM stock. At least it'll be over quickly for new investors. Not like us, waiting around for 12 years or more.

Yes, maybe, but that's what lawyers are for. If 737 was as good as some here think. Pharma would be kicking the CPF doors in and judging by the deal they announced, they aren't. So at some point and for me it was a while ago, you have to start thinking maybe 737 isn't all it is cracked up to be. However, I still think it's worth £800 million if it goes into combo trials.

It might be cynical but we don't need the drugs to work to make money here, we just need pharma to think they will work.

I think I have a different view of 737 than most here. It is my opinion that the efficacy of 737 in combo isn't as cut and dried as we like to think it is. If it was, Sierra wouldn't have given it away. Nothing to do with Sixth Capital or CPF. phama, including GSK, will have looked at the data and translational studies and they are not convinced yet. It's as simple as that, yes it has potential but someone needs to spend some cash to prove it.

Literally, no one here would call you that.

I personally think a bridging loan to cover the essentials with warrants as collateral. I also think there is probably scope for a JV between SAR and CPF for the development of 1802. That would set the SP on fire if 1802 was moving at pace through trials and It would be worth the percentage of ownership we would have to give away. Don't forget if 1801 passes 1a then 1802 goes straight into patients. We might have enough preliminary data from 1a to make this deal now.

I'm sure they are focused on the problem at hand now, Gunner. The damage was done 2 years ago, they should have raised back when a discount would've meant £1.50. Tim has stated a few occasions they wouldn't never pass up the opportunity to raise cash. Seems that something was happening back then to make them think they wouldn't need it.

Ah, what a saint you are. Maybe some people don't need any help?

Yeah, Silver, I know what you mean but for me, I am genuinely only buying with spare cash each month. If I lose, its only money that I would have spent on beer and going out, so no great loss. I'll feel better if we get to the end of the day without a bad news, Friday RNS. Interim results are due next week. There will have to be an RNS for that and with that, a forward-looking statement, which should have some clarification of our cash runway. I'm not buying today but today could be the last chance to get in this low.

I'm not sure why you want others to justify their strategy? Sell, short, hold or buy. It's up to you. I know why I'm buying and I'm happy with my decision. What I won't do though is to try and scare others so I can make a few pounds.